Free tool
FAERS Monitor: Qfitlia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219019 or its brand name (Qfitlia, Fitusiran Sodium). Reports on generic versions are filed under their own applications.
Reports
56
Serious
23
41% of reports
Hospitalization
13
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemorrhage17
- arthralgia9
- off label use8
- contusion7
- chest pain5
- haemarthrosis5
- condition aggravated4
- pain4
- pain in extremity4
- compartment syndrome3
- fall3
- hepatic enzyme increased3
- muscle haemorrhage3
- peripheral swelling3
- spontaneous haemorrhage3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 12 |
| 2026 | 43 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,103 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| spontaneous haemorrhageSignal | 3 | 1101.5 | 365.7 | 2,283 |
| compartment syndromeSignal | 3 | 432.5 | 143.7 | 895 |
| muscle haemorrhageSignal | 3 | 281.0 | 93.4 | 580 |
| haemarthrosisSignal | 5 | 209.7 | 90.8 | 840 |
| haemorrhageSignal | 17 | 61.1 | 41.1 | 950 |
| contusionSignal | 7 | 27.3 | 13.7 | 153 |
| hepatic enzyme increasedSignal | 3 | 16.5 | 5.5 | 30 |
| chest painSignal | 5 | 10.1 | 4.4 | 33 |
| arthralgiaSignal | 9 | 8.1 | 4.5 | 50 |
| peripheral swellingSignal | 3 | 7.3 | 2.4 | 11 |
| pain in extremitySignal | 4 | 5.1 | 2.0 | 10 |
| condition aggravatedSignal | 4 | 4.9 | 1.9 | 9 |
| off label useSignal | 8 | 3.4 | 1.8 | 12 |
| fall | 3 | 3.4 | 1.1 | 3 |
| pain | 4 | 2.4 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.